facebooktwitterlinkedin
Health Resources Hub / Heart Health / Heart Failure

Camzyos Keeps Easing Heart Obstruction in Teens With HCM Over 56 Weeks

New 56-week results from the phase 3 SCOUT-HCM trial back up the September FDA approval of Camzyos for children and teens with symptomatic obstructive HCM.

By

Lana Pine

Published on November 16, 2026

Fact checked by:

Afton Woodward

4 min read

Teens with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) who took Camzyos (mavacamten) kept their improvements in blood flow through the heart for more than a year, with no new safety concerns, according to new results from the phase 3 SCOUT-HCM trial.

Bristol Myers Squibb, which makes Camzyos, presented the 56-week findings as a late-breaker at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on Nov. 6, 2026, in Chicago. The results come about two months after the U.S. Food and Drug Administration (FDA) approved Camzyos for children and teens weighing 30 kilograms (66 pounds) or more with symptomatic oHCM, making it the first approved treatment for these younger patients in the U.S.

A Thickened Heart That Blocks Blood Flow

Hypertrophic cardiomyopathy is an inherited condition in which the heart muscle becomes abnormally thick. In the obstructive form, the thickened muscle narrows the path blood takes as it leaves the heart’s main pumping chamber, an area called the left ventricular outflow tract (LVOT). That blockage can cause shortness of breath, chest pain, fatigue and trouble exercising.

Camzyos is a cardiac myosin inhibitor. It targets the overly forceful squeezing of the heart muscle that drives oHCM, which can reduce the blockage and lower pressure inside the heart. The FDA first approved it for adults with symptomatic oHCM in 2022.

Following Teens for More Than a Year

SCOUT-HCM enrolled 44 patients ages 12 to 17 with symptomatic oHCM. During the first 28 weeks, participants were randomly assigned to take Camzyos or a placebo once daily, without knowing which they received. Most were already on other heart medications, including beta-blockers.

Of the 44 participants, 43 finished that first phase. From Week 28 to Week 56, all of them took Camzyos, including those who had been on placebo.

Lasting Drops in Obstruction

Teens who took Camzyos for the full 56 weeks saw their Valsalva LVOT gradient, a measure of how much the outflow tract is blocked while bearing down, fall by an average of 48.1 mmHg from the start of the study. At the outset, the average gradient was 78 mmHg in the Camzyos group and 81 mmHg in the placebo group. Teens who switched from placebo to Camzyos at Week 28 saw a similar reduction.

Participants in both groups also showed meaningful improvements in several secondary measures, according to the company.

“This is the first time a cardiac myosin inhibitor has been evaluated in this patient population for this length of time and in a double-blind study,” said Cordula Wolf, M.D., associate professor at Technical University of Munich University Hospital German Heart Centre.

Keeping an Eye on Heart Function

Because Camzyos eases how forcefully the heart contracts, doctors monitor how well the heart is pumping, measured as left ventricular ejection fraction (LVEF), with regular echocardiograms. In SCOUT-HCM, no participant’s LVEF fell below 50% during the 56 weeks.

Treatment-related side effects were uncommon. Teens on Camzyos for all 56 weeks had five treatment-related adverse events, two of them serious. Those who switched from placebo had one treatment-related adverse event and no serious ones during their 28 weeks on the drug.

Wolf said the results “serve as an important resource for health care providers and patients when discussing their care plan.”

Important Limits to Keep in Mind

SCOUT-HCM is a small trial, and the secondary measures were descriptive only. The 56-week results were shared at a scientific meeting and in a company news release and have not yet been published in a peer-reviewed journal. Participants can continue in an open-label extension for up to 144 more weeks, which may offer more information on long-term safety.

© 2026 MJH Life Sciences®

All rights reserved.